Abstract 952P
Background
Transarterial chemoembolization (TACE) in combination with lenvatinib has been reported in several exploratory clinical studies in Chinese patients with hepatocellular carcinoma (HCC). Studies have showed good tumor response and survival benefit for combination therapy based on TACE plus lenvatinib in patients with advanced HCC. A multicenter, real-world study was conducted to explore the efficacy and safety of TACE in combination with lenvatinib as initial treatment for unresectable HCC patients in a real-world setting (PROLONG study, NCT04560751).
Methods
This real-world study was conducted at 7 centers in China. Eligible patients were aged more than 18 years old, with HCC, CNLC stage IIb-IIIb with unresectable diseases, Child-Pugh ≤7, Eastern Cooperative Oncology Group (ECOG) performance status 0-1, no prior systemic therapy. All patients received TACE combined with lenvatinib, with or without immune checkpoint inhibitors. The primary endpoint was objective response rate (ORR), which was evaluated according to mRECIST, and secondary endpoints included organ-specific objective response rate, progression-free survival (PFS), AFP response rate and time to progression (TTP).
Results
A total of 197 patients were enrolled from August 2020 to February 2023, with 145 patients evaluable for efficacy. The ORR was 48.3% evaluated according to mRECIST, with a complete response (CR) rate of 8.3%, partial response (PR) rate of 40%. The disease control rate (DCR) was 86.2%. The median PFS was 10.2 months (95%CI, 5.9-14.5), and the median OS has not been reached. The most common adverse events (AE) were fever, elevated transaminases, and decreased platelets. No treatment-related grade 5 AE occurred.
Conclusions
Combination therapy based on TACE plus lenvatinib in patients with unresectable hepatocellular carcinoma showed promising efficacy in the real-world setting. No unexpected adverse events were observed.
Clinical trial identification
NCT04560751.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
946P - Sintilimab plus lenvatinib as conversion therapy in patients with unresectable hepatocellular carcinoma: A prospective, non-randomized, open-label, phase II, expansion cohort study
Presenter: Shichun Lu
Session: Poster session 18
947P - The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma: A phase Ib/II clinical trial
Presenter: Li Bai
Session: Poster session 18
949P - Regorafenib combined with immunotherapy versus regorafenib as second-line therapy in patients with advanced hepatocellular carcinoma: A multicenter real-world study
Presenter: Bin-Kui Li
Session: Poster session 18
953P - Tislelizumab plus regorafenib as second-line therapy for unresectable hepatocellular carcinoma (uHCC): A single-arm, phase II trial
Presenter: Zhongchao Li
Session: Poster session 18
954P - Radiotherapy combined with tislelizumab plus anlotinib as first-line treatment for hepatocellular carcinoma: A single arm, phase II clinical trial
Presenter: Guishu wu
Session: Poster session 18
955P - IMMUNIB trial (AIO-HEP-0218/ass): A single-arm phase II study evaluating safety and efficacy of immunotherapy with nivolumab in combination with lenvatinib in advanced hepatocellular carcinoma
Presenter: Arndt Vogel
Session: Poster session 18
956P - Phase II study of adjuvant tislelizumab combined with interferon-α and active surveillance in hepatocellular carcinoma patients with microvascular invasion
Presenter: Yixiu Wang
Session: Poster session 18